Carna Biosciences, Inc. (4572.T)
JPY 252.0
(1.2%)
JPY 252.0
(1.2%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 1.62 Billion JPY | 17.24% |
| 2022 | 1.38 Billion JPY | -31.27% |
| 2021 | 2.01 Billion JPY | 78.02% |
| 2020 | 1.13 Billion JPY | -64.66% |
| 2019 | 3.2 Billion JPY | 325.0% |
| 2018 | 754.69 Million JPY | 14.78% |
| 2017 | 657.51 Million JPY | -18.99% |
| 2016 | 811.59 Million JPY | -48.28% |
| 2015 | 1.56 Billion JPY | 156.51% |
| 2014 | 611.76 Million JPY | -20.7% |
| 2013 | 771.46 Million JPY | 51.02% |
| 2012 | 510.82 Million JPY | -13.79% |
| 2011 | 592.54 Million JPY | 3.63% |
| 2010 | 571.8 Million JPY | -16.77% |
| 2009 | 687.01 Million JPY | 37.52% |
| 2008 | 499.57 Million JPY | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 134.77 Million JPY | -25.49% |
| 2024 Q1 | 180.87 Million JPY | -80.22% |
| 2023 Q1 | 226.96 Million JPY | -22.04% |
| 2023 Q2 | 273.6 Million JPY | 20.55% |
| 2023 Q4 | 914.59 Million JPY | 334.03% |
| 2023 FY | 1.62 Billion JPY | 17.24% |
| 2023 Q3 | 210.72 Million JPY | -22.98% |
| 2022 Q2 | 284.89 Million JPY | -48.64% |
| 2022 FY | 1.38 Billion JPY | -31.27% |
| 2022 Q4 | 291.14 Million JPY | 13.7% |
| 2022 Q1 | 554.65 Million JPY | -59.84% |
| 2022 Q3 | 256.06 Million JPY | -10.12% |
| 2021 Q4 | 1.38 Billion JPY | 568.77% |
| 2021 FY | 2.01 Billion JPY | 78.02% |
| 2021 Q1 | 231.27 Million JPY | -19.05% |
| 2021 Q2 | 198.73 Million JPY | -14.07% |
| 2021 Q3 | 206.5 Million JPY | 3.91% |
| 2020 Q4 | 285.69 Million JPY | 6.63% |
| 2020 Q3 | 267.94 Million JPY | 9.52% |
| 2020 Q2 | 244.66 Million JPY | -26.98% |
| 2020 Q1 | 335.04 Million JPY | -2.93% |
| 2020 FY | 1.13 Billion JPY | -64.66% |
| 2019 FY | 3.2 Billion JPY | 325.0% |
| 2019 Q4 | 345.16 Million JPY | -14.02% |
| 2019 Q2 | 2.29 Billion JPY | 1247.83% |
| 2019 Q1 | 169.96 Million JPY | 1.27% |
| 2019 Q3 | 401.46 Million JPY | -82.48% |
| 2018 Q2 | 187.98 Million JPY | -10.96% |
| 2018 Q3 | 187.74 Million JPY | -0.12% |
| 2018 Q1 | 211.13 Million JPY | 21.19% |
| 2018 FY | 754.69 Million JPY | 14.78% |
| 2018 Q4 | 167.82 Million JPY | -10.61% |
| 2017 Q3 | 156.5 Million JPY | 19.67% |
| 2017 Q2 | 130.77 Million JPY | -33.28% |
| 2017 Q1 | 196.02 Million JPY | -14.92% |
| 2017 FY | 657.51 Million JPY | -18.99% |
| 2017 Q4 | 174.21 Million JPY | 11.32% |
| 2016 Q3 | 138.5 Million JPY | -36.29% |
| 2016 Q1 | 225.32 Million JPY | -22.85% |
| 2016 FY | 811.59 Million JPY | -48.28% |
| 2016 Q4 | 230.38 Million JPY | 66.34% |
| 2016 Q2 | 217.38 Million JPY | -3.52% |
| 2015 FY | 1.56 Billion JPY | 156.51% |
| 2015 Q3 | 142.25 Million JPY | -82.23% |
| 2015 Q4 | 292.05 Million JPY | 105.3% |
| 2015 Q2 | 800.63 Million JPY | 139.53% |
| 2015 Q1 | 334.25 Million JPY | 121.17% |
| 2014 Q2 | 138.02 Million JPY | -17.91% |
| 2014 FY | 611.76 Million JPY | -20.7% |
| 2014 Q1 | 168.13 Million JPY | -20.13% |
| 2014 Q3 | 154.47 Million JPY | 11.92% |
| 2014 Q4 | 151.12 Million JPY | -2.17% |
| 2013 Q1 | 177.04 Million JPY | 26.45% |
| 2013 Q4 | 210.51 Million JPY | -4.04% |
| 2013 Q3 | 219.37 Million JPY | 33.33% |
| 2013 Q2 | 164.53 Million JPY | -7.07% |
| 2013 FY | 771.46 Million JPY | 51.02% |
| 2012 Q3 | 114.22 Million JPY | -11.62% |
| 2012 Q4 | 140 Million JPY | 22.57% |
| 2012 FY | 510.82 Million JPY | -13.79% |
| 2012 Q2 | 129.24 Million JPY | 1.49% |
| 2012 Q1 | 127.34 Million JPY | -12.18% |
| 2011 Q1 | 158.22 Million JPY | 13.93% |
| 2011 Q3 | 135.13 Million JPY | -12.35% |
| 2011 Q4 | 145.01 Million JPY | 7.31% |
| 2011 FY | 592.54 Million JPY | 3.63% |
| 2011 Q2 | 154.17 Million JPY | -2.56% |
| 2010 FY | 571.8 Million JPY | -16.77% |
| 2010 Q1 | 163 Million JPY | -12.17% |
| 2010 Q3 | 109.22 Million JPY | -32.03% |
| 2010 Q4 | 138.88 Million JPY | 27.15% |
| 2010 Q2 | 160.69 Million JPY | -1.42% |
| 2009 FY | 687.01 Million JPY | 37.52% |
| 2009 Q1 | 162.62 Million JPY | 0.0% |
| 2009 Q2 | 156.17 Million JPY | -3.97% |
| 2009 Q3 | 182.62 Million JPY | 16.94% |
| 2009 Q4 | 185.58 Million JPY | 1.62% |
| 2008 FY | 499.57 Million JPY | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 4.77 Billion JPY | 65.915% |
| PRISM BioLab Co.,LTD | 112.92 Million JPY | -1339.783% |
| GNI Group Ltd. | 26.01 Billion JPY | 93.749% |
| Linical Co., Ltd. | 12.3 Billion JPY | 86.79% |
| Trans Genic Inc. | 13.08 Billion JPY | 87.573% |
| MEDINET Co., Ltd. | 661.54 Million JPY | -145.772% |
| Soiken Holdings Inc. | 5.15 Billion JPY | 68.481% |
| Cytori Cell Research Institute, Inc. | 1.56 Billion JPY | -4.198% |
| AnGes, Inc. | 152.98 Million JPY | -962.777% |
| OncoTherapy Science, Inc. | 610.11 Million JPY | -166.488% |
| Nxera Pharma Co., Ltd. | 12.76 Billion JPY | 87.264% |
| Immuno-Biological Laboratories Co., Ltd. | 816.7 Million JPY | -99.08% |
| NanoCarrier Co., Ltd. | 135.5 Million JPY | -1099.847% |
| CanBas Co., Ltd. | - JPY | -Infinity% |
| D. Western Therapeutics Institute, Inc. | 428.36 Million JPY | -279.558% |
| RaQualia Pharma Inc. | 1.9 Billion JPY | 14.481% |
| Chiome Bioscience Inc. | 682.46 Million JPY | -138.238% |
| Kidswell Bio Corporation | 2.43 Billion JPY | 33.125% |
| PeptiDream Inc. | 28.71 Billion JPY | 94.337% |
| Oncolys BioPharma Inc. | 63.03 Million JPY | -2479.22% |
| Ribomic Inc. | - JPY | -Infinity% |
| SanBio Company Limited | - JPY | -Infinity% |
| Healios K.K. | 121 Million JPY | -1243.71% |
| BrightPath Biotherapeutics Co., Ltd. | 72 Thousand JPY | -2258079.167% |
| Kubota Pharmaceutical Holdings Co., Ltd. | 39.88 Million JPY | -3976.238% |
| Delta-Fly Pharma, Inc. | - JPY | -Infinity% |
| StemRIM | - JPY | -Infinity% |
| CellSource Co., Ltd. | 4.51 Billion JPY | 63.954% |
| FunPep Company Limited | 530 Thousand JPY | -306671.509% |
| Kringle Pharma, Inc. | 69.25 Million JPY | -2247.854% |
| Stella Pharma Corporation | 269.49 Million JPY | -503.318% |
| TMS Co., Ltd. | - JPY | -Infinity% |
| Noile-Immune Biotech Inc. | 316.81 Million JPY | -413.193% |
| Cuorips Inc. | 23.1 Million JPY | -6937.871% |
| K Pharma,Inc. | 1 Billion JPY | -62.589% |
| Takara Bio Inc. | 43.5 Billion JPY | 96.263% |
| ReproCELL Incorporated | 2.42 Billion JPY | 33.003% |
| PhoenixBio Co., Ltd. | 1.71 Billion JPY | 5.214% |
| StemCell Institute Inc. | 2.48 Billion JPY | 34.471% |
| Japan Tissue Engineering Co., Ltd. | 2.51 Billion JPY | 35.331% |
| CellSeed Inc. | 190.13 Million JPY | -755.128% |